bims-ovdlit Biomed News
on Ovarian cancer: early diagnosis, liquid biopsy and therapy
Issue of 2026–11–15
seven papers selected by
Lara Paracchini, Humanitas Research



  1. Nat Med. 2026 Nov 10.
    Jochen Wilhelm, Amit Kumar, Hitesh Vasiyani, Narsimha Mamidi, Zhaoyu Sun, Aenya Gogna, Praveen Bhoopathi, Keshav C Gogna, Chelsea Salyer, Amy Lu, Kranthi Kumar Chougoni, Ava N Gardner, Andrew S Poklepovic, Masaki Nagane, Kumari S Shree, Emad A Rakha, Karuppaiyah Selvendiran, George L Maxwell, Jamie N Bakkum-Gamez, Shariska Petersen Harrington, Elnaz Abbasi Farid, Nadia Traficante, David Bowtell, Christopher D Collier, Rebecca Z Drexler, Christine Kramer, Mary M Mullen, Alexandar Tzankov, Kirsten D Mertz, Jun Watanabe, Shimpei Nagai, Tatsuyuki Chiyoda, Wataru Yamagami, Kenta Masuda, Elena Garre, Göran Landberg, David L Kolin, Calla O'Connor, Sarah A Ackroyd, Bodour Salhia, Paola A Gehrig, Aanya Singh, Tytus Bernas, Anusha Challa, Sriram Sriperumbuduri, Nolan A Wages, Jordan Lewis, Lien Hoang, Janice S Kwon, Jasmin D Haslbauer, Mark P Kühnel, T Rinda Soong, Sarah Taylor, Carlos Zuazo, Tiffany Beck, Michael J Demeure, Marc R Radke, Sourat Darabi, Denise Connolly, Barbara S Norquist, Nozomi Yachida, Kazuaki Suda, Kosuke Yoshihara, Tu-Yung Chang, Patrick Martin, Kyoung Jae Won, Tian-Li Wang, Ie-Ming Shih, Thomas Russell Pisanic, Tanvir K Dhaliwal, Vandanaa Jayaprakash, Bukola Adeshina, Seungpyo Hong, Ana Blanca, David R Braxton, Cesar M Castro, Elizabeth M Swisher, Allan Tsung, Ernst Lengyel, Susan Domchek, William L Redmond, Yonglun Luo, Ole Mogensen, Robert A Winn, Bo R Rueda, Ronny Drapkin, Andrew K Godwin, Ronald J Buckanovich, Kenneth P Nephew, Rafael J Luque, Antonio Lopez-Beltran, Robert L Coleman, Daniel Von Hoff, David Sidransky, Maximilian Ackermann, Danny Jonigk, Steven R Grossman, Ranjit Manchanda, Rajan Gogna, Esha Madan.
      Flower-Win/Lose signaling underlies a tumor-host fitness conflict in ovarian cancer, in which tumor-derived exosomal Tu-stroma reduces the fitness of surrounding host cells, favoring tumor expansion within host tissues. High-grade serous carcinoma (HGSC), the most prevalent histotype of epithelial ovarian cancer and leading cause of ovarian-cancer-related mortality, arises from serous tubal intraepithelial carcinoma (STIC), a noninvasive precursor typically identifiable only by histopathologic examination of excised fallopian tube tissue. Here we evaluated Tu-stroma, a tumor-associated long noncoding RNA enriched in serum extracellular vesicles (EVs), as a circulating biomarker in STIC and early-stage HGSC, representing the earliest histopathologically defined phases of disease. Tu-stroma was quantified in serum EVs from 506 individuals with histologically normal adnexa, benign-adnexal lesions, isolated STIC and HGSC across International Federation of Gynecology and Obstetrics (FIGO) stages I-IV. Normalized EV Tu-stroma ΔCT values were elevated in STIC (n = 43) and HGSC (n = 232) versus controls (n = 143) and benign-adnexal lesions (n = 88), including premenopausal women (controls = 57, benign = 34, STIC = 32, HGSC = 88). In paired receiver operating characteristic analyses, Tu-stroma showed higher discrimination than cancer antigen 125 (CA125) for STIC versus controls (area under the curve (AUC) = 0.99 versus 0.59, P < 0.001) and benign-adnexal masses (0.99 versus 0.31, P < 0.001), and for HGSC versus controls (AUC = 0.99 versus 0.96, P = 0.001) and benign-adnexal masses (0.98 versus 0.84, P < 0.001). Tu-stroma showed no systematic elevation across inflammatory or physiologic comparators (n = 116) or nonovarian malignancies (n = 160), each assessed against healthy controls (n = 100), supporting disease-context specificity. Modeled risk-enriched contexts yielded predictive values compatible with intended-use populations. These findings identify Tu-stroma as a candidate EV-RNA marker associated with pre-invasive and early HGSC biology. Prospective evaluation in consecutively enrolled real-world cohorts is required to validate diagnostic performance, predictive value and clinical utility.
    DOI:  https://doi.org/10.1038/s41591-026-04732-9
  2. Int J Gynaecol Obstet. 2026 Nov 09.
      Risk-reducing gynecologic surgery is an established preventive option for women with selected hereditary cancer predisposition syndromes. In BRCA1 and BRCA2 pathogenic variant carriers, observational studies associate risk-reducing salpingo-oophorectomy with lower tubo-ovarian cancer incidence and mortality. In Lynch syndrome, hysterectomy is associated with reduced endometrial cancer incidence, while ovarian removal requires gene-specific assessment of age, menopausal status, family history, and preferences. Accumulating pathologic and molecular evidence supports a distal tubal origin for many high-grade serous carcinomas, informing complete salpingectomy and meticulous pathology and providing a biologic rationale for investigating salpingectomy with delayed oophorectomy. Prospective preference studies associate this staged strategy with better menopause-related quality of life, but selection bias remains relevant and oncologic non-inferiority is unestablished. This narrative review critically integrates observational findings, risk estimates, guideline recommendations, and expert consensus into a clinical framework for patient selection, procedure choice, timing, counseling, and survivorship. Prevention planning should address fertility, surgical menopause, hormone therapy, residual peritoneal cancer risk, and unequal access to testing and specialist care.
    Keywords:  BRCA; Lynch syndrome; hereditary cancer; ovarian cancer prevention; risk‐reducing salpingo‐oophorectomy; shared decision‐making; surgical timing
    DOI:  https://doi.org/10.1002/ijgo.71492
  3. WIREs Mech Dis. 2026 Nov-Dec;18(6):pii: e70019. [Epub ahead of print]18(6):
      Conventional tissue biopsy remains the clinical standard for diagnosing many cancers, but it provides only a spatially restricted and temporally limited view of disease. Cell-free DNA (cfDNA) is a minimally invasive source of molecular information that may reflect temporal changes in tissue injury, clonal evolution, and epigenetic remodeling. This review distinguishes early tumorigenesis, premalignant states, preinvasive disease, and early-stage cancer, and examines how mutational profiling, fragmentomics, DNA methylation, and extracellular vesicles can be used to investigate molecular events across this continuum. The conceptual contribution is to frame cfDNA as a longitudinal readout of somatic evolution rather than solely a one-time cancer detection assay, while distinguishing direct measurements from computational inferences. We also discuss clonal hematopoiesis, signal dilution, the lack of validated reference standards, and the mismatch between dynamic tumor evolution and static biomarker assays. Longitudinal and multimodal analyses are biologically promising; however, current evidence does not yet demonstrate that cfDNA can directly or continuously monitor malignant transformation. In the near term, its value may lie primarily in risk stratification, mechanistic research, and rigorously validated surveillance of selected high-risk populations.
    Keywords:  cell‐free DNA; early cancer detection; fragmentomics; multiomics integration; tumorigenesis
    DOI:  https://doi.org/10.1002/wsbm.70019
  4. Nat Genet. 2026 Nov 11.
      Germline pathogenic BRCA1 variants predispose women to breast and ovarian cancer. Despite accumulation of functional evidence, over half of reported single-nucleotide variants in BRCA1 lack a definitive clinical interpretation. Furthermore, the consistency of variant effects across cell types remains largely unexplored. Here we performed saturation genome editing (SGE) of BRCA1 in HAP1 cells to score 4,113 previously unassayed variants. Additionally, we developed an SGE assay in human mammary epithelial cells (HMECs), allowing comparison of effects across cell lines, drug treatments and genetic backgrounds. We identified 538 variants impacting gene function through distinct mechanisms. HAP1 function scores discriminate between known pathogenic and benign variants with near-perfect accuracy. Intriguingly, however, nearly half of HAP1 loss-of-function variants scored neutrally in HMECs. We show that discordantly scored variants are hypomorphic and confer intermediate cancer risk. Overall, this work demonstrates how performing SGE across cell models improves the functional interpretation of rare variants.
    DOI:  https://doi.org/10.1038/s41588-026-02832-3
  5. Lancet. 2026 Nov 12. pii: S0140-6736(26)01600-4. [Epub ahead of print]
      Lynch syndrome is the most common inherited cancer predisposition syndrome, affecting approximately one in 350-450 individuals, yet the majority of carriers remain undiagnosed, representing a substantial and preventable public health burden. Caused by germline pathogenic variants in DNA mismatch repair (MMR) genes, Lynch syndrome confers markedly elevated and heterogeneous risks of colorectal, endometrial, and multiple extracolonic cancers. Advances in molecular diagnostics, particularly universal tumour testing for MMR deficiency, have transformed case identification and enabled targeted germline testing and cascade screening of relatives at risk. Despite these advances, implementation remains inconsistent, with substantial attrition across diagnostic pathways and inequities in access to care. Preventive strategies-including colonoscopic surveillance, aspirin chemoprevention, and risk-reducing surgery-are effective but require gene-specific and individualised application. Therapeutically, the immunogenic biology of MMR-deficient tumours has positioned Lynch syndrome at the forefront of precision oncology, with immune checkpoint inhibitors delivering substantial benefit and emerging vaccine strategies offering promise for cancer interception. In this Review, we provide an integrated overview of Lynch syndrome across the continuum of care, highlighting advances in biology, diagnosis, prevention, and treatment, while emphasising the crucial need to align scientific progress with equitable and effective health-system delivery.
    DOI:  https://doi.org/10.1016/S0140-6736(26)01600-4
  6. Ann Oncol. 2026 Nov 13. pii: S0923-7534(26)08683-7. [Epub ahead of print]
       BACKGROUND: Detection of circulating tumor DNA (ctDNA) harboring mutations that match those identified in resected tumor tissue signals occult residual disease after curative-intent surgery. Such patients are considered minimal residual disease (MRD)-positive and at high risk for recurrence and death. Few studies have shown that therapeutic intervention can alter recurrence risk in MRD-positive patients. We evaluated whether PD-1 blockade could reduce recurrence in MRD-positive patients with mismatch repair-deficient (dMMR) tumors after curative-intent resection regardless of tumor site of origin.
    PATIENTS AND METHODS: We initiated a prospective phase II interventional study in patients who had undergone curative-intent resection of early-stage dMMR tumors from any anatomic site. Postoperative MRD status was assessed by first identifying those patients who had detectable ctDNA and then confirming the ctDNA relevance to MRD by matching mutations detected in ctDNA to somatic mutations detected in resected tumor tissue. Confirmed MRD-positive patients received 6 months of PD-1 blockade and were evaluated for ctDNA clearance and 24-month recurrence-free survival (RFS). MRD-negative patients underwent observation.
    RESULTS: We screened 184 patients with early-stage dMMR solid tumors after curative resection and tumor sequencing with ctDNA testing for MRD assessment. Twenty-three patients (12.5%) were MRD-positive; after excluding one assigned to placebo and three with synchronous radiographic disease, 19 were eligible. Six developed recurrences before pembrolizumab initiation despite being disease-free at enrollment. The remaining 13 MRD-positive patients received 6 months of PD-1 blockade. ctDNA clearance at 6 months was achieved in 11 of 13 patients (85%). Five treated patients (38%) developed recurrence during follow-up. Median follow-up for the MRD-positive patients was 59 months (95% CI: 52-NR). Among 152 MRD-negative patients managed with observation, 14 (9%) developed recurrence during follow-up; 2-year RFS was 92%.
    CONCLUSIONS: These findings provide evidence that ctDNA-guided adjuvant therapy may offer clinical benefit in dMMR tumors regardless of tissue of origin.
    Keywords:  MSI-high; adjuvant therapy; circulating tumor DNA; dMMR; immune checkpoint blockade; minimal residual disease; tumor agnostic therapy
    DOI:  https://doi.org/10.1016/j.annonc.2026.11.005
  7. Cancer Res. 2026 Nov 13.
      Epithelial ovarian cancers (EOCs) comprise biologically distinct histotypes that arise within shared anatomical niches where tumor-stroma interactions shape tumor behavior and therapeutic response. However, most classification frameworks rely on bulk profiling that conflates epithelial and stromal contributions, limiting the understanding of crosstalk between the different compartments. Here, we performed compartment-resolved transcriptomic and epigenomic profiling of matched carcinoma and stroma across clear cell (CCOC), endometrioid (ENOC), and high-grade serous ovarian cancers (HGSC). Carcinoma profiles segregated strongly by histotype, whereas stromal profiles showed minimal histotype specificity and instead resolved into four shared groups (S1-S4). The S4 subtype, marked by a desmoplastic, myofibroblast-rich program, was enriched in omental tumors and corresponded to the HGSC C1/Mesenchymal signature. This subtype largely reflected tumor-extrinsic programs and was present beyond HGSC. Compartment-resolved analyses also refined the interpretation of other molecular carcinoma subtypes and revealed distinct carcinoma-intrinsic EMT-like programs. Together, these findings define a histotype-agnostic stromal architecture across epithelial ovarian cancers, clarify the cellular basis of canonical high-grade serous molecular subtypes, and reveal carcinoma-intrinsic EMT programs. This study underscores the value of physically separating epithelial and stromal compartments before molecular analysis and position this dataset as a multi-purpose reference resource for the EOC research community.
    DOI:  https://doi.org/10.1158/0008-5472.CAN-26-1330